Stemline - Model CD123 - Multiple Malignancies
CD123 is expressed on multiple malignancies including BPDCN, AML, certain myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), B-cell acute lymphoid leukemia (B-ALL), hairy cell leukemia, and Hodgkin’s and certain non-Hodgkin’s lymphomas. In addition to expression on tumor bulk, CD123 expression has been reported on the cancer stem cells (CSCs), of certain hematologic cancers including AML, CML, MDS, and potentially T-cell ALL. In addition, elevated CD123 expression has been correlated with poor prognosis in certain hematologic cancers.
-
Most popular related searches
Details
Notably, neoplastic CD123+ pDCs, which are the cell of origin for BPDCN, have been found in a number of myeloid neoplasms, including CMML, MDS, and AML, and are associated with poor prognosis. Additionally, neoplastic CD123+ pDCs have also been reported in the microenvironment of certain tumors including multiple myeloma, CMML and other MPNs, and in certain solid tumors where they could play a tumor-promoting role. Preclinical experiments in multiple myeloma have shown these pDCs to have a tumor-promoting effect. Neoplastic CD123+ pDCs have also been implicated in the pathogenesis of certain autoimmune diseases, including scleroderma and cutaneous lupus, and are under evaluation as a potential therapeutic target for these conditions.
Customer reviews
No reviews were found for Stemline - Model CD123 - Multiple Malignancies. Be the first to review!